Evoked Pain Analgesia in Chronic Pelvic Pain Patients Using Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation

Vitaly Napadow, PhD,*† Robert R. Edwards, PhD,† Christine M. Cahalan, BA,† George Mensing, BA,† Seth Greenbaum, BA,† Assia Valovska, MD,† Ang Li, BA,* Jieun Kim, PhD,* Yumi Maeda, PhD,* Kyungmo Park, PhD,§ and Ajay D. Wasan, MD, MSc†‡

*Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts; Departments of †Anesthesiology, and

§Department of Biomedical Engineering, Kyunghee University, Yongin, Republic of Korea

Reprint requests to: Vitaly Napadow, PhD, Martinos Center for Biomedical Imaging, 149 Thirteenth St. #2301, Charlestown, MA 02129, USA. Tel: 617-724-3402; Fax: 617-726-7422; E-mail: vitaly@nmr.mgh.harvard.edu.

Abstract

Objective. Previous vagus nerve stimulation (VNS) studies have demonstrated antinociceptive effects, and recent noninvasive approaches, termed transcutaneous-vagus nerve stimulation (t-VNS), have utilized stimulation of the auricular branch of the vagus nerve in the ear. The dorsal medullary vagal system operates in tune with respiration, and we propose that supplying vagal afferent stimulation gated to the exhalation phase of respiration can optimize t-VNS.

Design. Counterbalanced, crossover study.

Patients. Patients with chronic pelvic pain (CPP) due to endometriosis in a specialty pain clinic.

Interventions/Outcomes. We evaluated evoked pain analgesia for respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) compared with nonvagal auricular stimulation (NVAS). RAVANS and NVAS were evaluated in separate sessions spaced at least 1 week apart. Outcome measures included deep-tissue pain intensity, temporal summation of pain, and anxiety ratings, which were assessed at baseline, during active stimulation, immediately following stimulation, and 15 minutes after stimulus cessation.

Results. RAVANS demonstrated a trend for reduced evoked pain intensity and temporal summation of mechanical pain, and significantly reduced anxiety in N = 15 CPP patients, compared with NVAS, with moderate to large effect sizes ($\eta^2 > 0.2$).

Conclusion. Chronic pain disorders such as CPP are in great need of effective, nonpharmacological options for treatment. RAVANS produced promising antinociceptive effects for quantitative sensory testing (QST) outcomes reflective of the noted hyperalgesia and central sensitization in this patient population. Future studies should evaluate longer-term application of RAVANS to examine its effects on both QST outcomes and clinical pain.

Key Words. Chronic Pain; TENS; Transcutaneous Electrical Nerve Stimulation (TENS); Acupuncture

Introduction

Previous vagus nerve stimulation (VNS) studies have demonstrated antinociceptive effects [1], particularly in patients with depression [2]. However, moderate morbidity has been associated with the surgical procedure and maintenance of VNS [3]. Furthermore, it is still unclear whether VNS is an analgesic treatment in general or for a specific chronic pain syndrome. In this study, we propose a novel, noninvasive procedure based on the neurobiology of VNS treatment—respiratory-gated auricular vagal afferent nerve stimulation (RAVANS), which synchronizes stimulation to the respiratory cycle. The auricular branch of the vagus (ABV) nerve extends to the pinna of the ear and can be electrically depolarized with minimal invasiveness, a procedure referred to as transcutaneous-vagus nerve stimulation (t-VNS) [4,5]. Respiration is known to cyclically modulate activity in both input and output vagal brainstem regions. Hence, the brainstem vagal input–output system operates in tune with respiration and t-VNS can be synchronized with respiratory events to better optimize
stimulation, which may improve the analgesic benefits of VNS.

Multiple studies have suggested that VNS can produce antinociceptive effects. Studies in a rat model have linked stimulation of vagal afferents with antinociception [6,7]. Both animal studies [8] and a recent study in humans [9] suggest that during active VNS, pronociception can occur when stimulus intensity is low, but antinociceptive effects predominate when stimulus intensity is high (non-noxious, detectable stimulation, in the mA range). Moreover, Kirchner et al. found in humans that chronic VNS (at mean of 0.7–1.4 mA) raises pain thresholds for both tonic pinch and heat pain, as well as mitigating pain windup phenomenon for mechanical stimuli [10,11]. These results demonstrate promising analgesic effects of VNS, although it is unclear whether findings involving implanted vagal stimulators in patients with intractable seizure disorders will generalize to trials of t-VNS in patients with chronic pain.

Classical VNS involves surgery, with the stimulator lead implanted within the carotid sheath, wrapped around the vagus nerve in the left neck [12]. This can induce morbidity stemming either from coactivation of efferent vagal fibers (e.g., bradycardia, asystole [13], larynx/pharynx disorders [14], and dysphagia [15]), or from infection or hardware failure [15]. Ultimately, as the mechanisms for VNS likely involve afferent, and not efferent vagal fibers [16], isolation of afferent fibers in vagal stimulation would eliminate potential negative effects due to efferent stimulation, while accessing these fibers without surgical intervention would eliminate infection-associated morbidity. In summary, there are many advantages to a minimally invasive and less costly vagal nerve stimulation device, which would serve to benefit a larger number of chronic pain patients.

The analgesic mechanisms of VNS have not been fully elucidated, but are likely mediated by afferent (not efferent) input to supraspinal brain regions [16]. Vagal afference is relayed to the nucleus tractus solitarius (NTS) in the medullary brainstem. More importantly, the NTS also receives somatosensory afference via the ABV nerve from specific portions of the auricle [17]. ABV afference is transmitted to both the NTS [17] and the spinal trigeminal nucleus (SpV) [18] by neurons located in the superior (jugular) ganglion of the vagus nerve. Respiration can modulate NTS activity directly (the lungs are innervated by the vagus nerve) and indirectly. In regard to the latter, inspiration increases venous return to the thorax, which increases arterial pressure, and hence vagal (and glossopharyngeal nerve) afference to the NTS via aortic and carotid baroreceptors, respectively [19]. The NTS then inhibits efferent vagal outflow to the heart [20,21], leading to a transient inspiratory tachycardia with every breath. This feedback loop is termed “respiratory sinus arrhythmia” [22]. Hence, the dorsal medullary vagal system operates in tune with respiration, and we propose that supplying vagal afferent stimulation gated to the exhalation phase of respiration (i.e., when thoracic baroreceptor afference does not enter the NTS) will optimize t-VNS therapy (see Figure 1 for schematic). Furthermore, such intermittent, irregular stimulation (i.e., varying with respiration) will also mitigate classical neuronal adaptation/accommodation, which can occur with continuous stimulation of NTS neurons [23].

While VNS is a general analgesic mechanism at the level of the brain, perhaps enhancing the activity of descending inhibitory systems, the vagus nerve has widespread projections throughout the abdominal and pelvic viscera. Thus, a likely target of VNS in initial clinical use could be abdominal and/or pelvic pain. Chronic pelvic pain (CPP) is a syndrome in urgent need of innovative and effective therapies [24]. CPP encompasses a number of common and debilitating syndromes including interstitial cystitis, endometriosis-mediated pain, and cancer pain [25]. Evidence from quantitative sensory testing (QST) studies has indicated that hyperalgesic mechanisms and central sensitization play a role in the chronicity and severity of this pain syndrome [26–28], supporting the use of QST measures as primary outcomes in evaluating potential therapeutic interventions for pelvic pain. In this study, we evaluated the effects of RAVANS on evoked, experimental pain ratings in patients with CPP due to endometriosis, using a counterbalanced crossover design. Patients completed two sessions utilizing QST evaluations before and after either RAVANS or an active control procedure, non-vagal auricular stimulation (NVAS). This was identical to RAVANS, except for the auricular location of stimulation. We hypothesized that RAVANS would produce greater evoked pain analgesia compared with the NVAS control.

Methods

Our randomized, crossover, pilot study was conducted at the Pain Management Center in the Department of Anesthesiology at Brigham and Women’s Hospital in Boston, MA. All patients completed informed consent procedures according to the protocol approved by the Partners Human Research Committee.

Subjects

In an effort to select a more homogeneous pelvic pain condition, patients with CPP due to endometriosis were recruited from the Pain Management Center of Brigham and Women’s Hospital. However, we recognize that endometriosis-linked CPP is difficult to classify and characterize as well, and that the etiology of pain is often unclear. For this initial study of RAVANS treatment, we targeted a sample size of approximately 15 patients. Crossover studies in patient groups that use QST as outcome measures often employ sample sizes of 20 or lower (e.g., N = 10 in Staahl et al. [29]).

Inclusion criteria consisted of the following: 1) female volunteers between 21 and 64 years of age with CPP for more than 6 months thought to be due to endometriosis by self-report (6 months of chronic pain is the criteria most often used in CPP research [24]); 2) confirmed by determination of a gynecologist or pain physician specializing in
pelvic pain (AV); 3) average pain intensity of \( \geq 4 \) on a scale from 0 to 10; and 4) at least an eighth grade English-reading level. In addition, exclusion criteria consisted of the following: 1) any interventional procedure for CPP 2 weeks prior to the study or during the 2-week study period, such as lumbar epidural steroids, nerve root blocks, etc.; 2) any etiology for CPP due to a known other local somatic lesion for the pain (e.g., fibroids) documented by the patient’s gynecologist, surgery, and/or imaging; 3) opioid usage, either oral or intrathecal; 4) surgical therapy in the previous 12 weeks, the intent to undergo surgery during the study period, or any clinically unstable systemic illness that is judged to interfere with the trial; 5) nonambulatory status; 6) history of severe cardiac or nervous system disease; 7) cancer or other malignant disease; and 8) pregnancy.

We did not evaluate study subjects during a specific phase of menstrual cycle. While the effects of menstrual cycle phase on pain sensitivity have been controversial [30], we chose not to control for this factor as 1) we anticipated that multiple subjects would be menopausal due to either posthysterectomy or other endometriosis treatment; 2) our study outcomes focused on within-session change scores; and 3) multiple subjects would be on oral contraceptives that are known to blunt any potential cycle-related variability in pain sensitivity [31,32].

**Session Protocol**

Subjects completed two experimental sessions, spaced at least 1 week apart, although given the duration of the treatment, we did not expect any carryover effects. The two sessions included either RAVANS (patent pending by Massachusetts General Hospital, not by the authors) or NVAS, occurring in a counterbalanced order.

Subjects were seated in a reclined position for both sessions. During the RAVANS stimulation session, two 0.20 x 1.5 mm modified press-tack electrodes (DBC, Korea and Vinco, China) were inserted in the left ear. Auricular locations were 1) the cymba concha and 2) the slope between the antihelix and cavum concha (Figure 2). These locations were chosen based on previous knowledge of vagus innervation of the human auricle. While variability exists, anatomic dissection in 7 cadavers (14

---

**Figure 1** Schematic of integrative innervation of the nucleus tractus solitarius (NTS). The NTS in the medulla integrates afferent inputs from the cervical vagus (X, e.g., aortic arch baroreceptors and lungs), glossopharyngeal nerve (IX, e.g., carotid baroreceptors), and auricular branch of the vagus (ABV). NTS input to higher brain regions processing different aspects of pain is thought to underlie the antinociceptive effects of vagus nerve stimulation. SpV = trigeminal nucleus; PB = parabrachial nucleus; LC = locus ceruleus; PAG = periaqueductal gray; hyp = hypothalamus; amygdale; thal = thalamus; ins = insula; ACC = anterior cingulate cortex; PFC = prefrontal cortex; S1 = primary somatosensory cortex.
ears) found that the cymba concha, antihelix, and cavum concha were innervated by the afferent branch of the vagus nerve in 100%, 75%, and 45% of ears, respectively [33]. During the control, NVAS, procedure, two electrodes were inserted into the ear lobe of the left auricle. Peuker and Filler found that the ear lobe was innervated by the great auricular nerve in 100% of ears studied [33]. The stimulus duration, intensity, pulse frequency, and all other stimulation parameters were the same between RAVANS and NVAS. As all aspects of the protocol including transcutaneous electrical stimulation parameters, but not site of stimulation, were matched in the two treatment conditions, NVAS should be considered an active control.

Electrical stimulation was provided by a Cefar Acus II (Cefar Medical, Lund, Sweden). Stimuli consisted of rectangular pulses with 450 μS pulse width, delivered at 30 Hz. Stimulus duration was 0.5 second and was gated to the exhalation phase of respiration (see below). Current intensity was set to achieve moderate to strong (but not painful) sensation, and pulse frequency/duration was set following pilot testing to achieve a subjectively comfortable stimulus sensation.

Respiratory gating for stimulation required real-time evaluation of the respiratory cycle. A pneumatic belt was placed around the subject’s lower thorax. Low-compliance tubing connected this belt to a pressure transducer (PX138-0.3DS5, Omegadyne, Inc., Sunbury, OH, USA), thereby producing voltage data that corresponded to changes in respiratory volume [34]. The voltage signal from the transducer was acquired by a laptop-controlled device (National Instruments USB DAQCard 6009, 14 bit i/o, with LABVIEW 7.0 data acquisition software; Austin, TX, USA). Computer code detected end-inspiration and end-expiration in real-time and a transistor-transistor logic (TTL) signal was output to a miniature high-frequency relay (G6Z-1P-DC5, Omron Electronics Components, Schaumburg, IL, USA). The TTL pulse was output to the relay 0.5 second after end-inspiration (i.e., during expiration), which allowed stimuli to pass to the ear electrodes for 0.5 second. Real-time evaluation of respiratory cycle is non-trivial, and an adaptive threshold detection method was employed. Correct expiratory-cycle stimulation was confirmed in real-time by the experimenter via running chart of the respiration signal and stimulus pulse. Post hoc review of these tracings was also performed and demonstrated accurate expiratory stimulation.

**Physiological Monitoring**

In addition to QST and clinical outcomes, we also collected physiological monitoring data, as our RAVANS...
intervention was mediated by the afferent vagus nerve, and effenter vagal feedback may have also been affected at medullary and higher brain levels. We collected both respiratory and electrocardiography (ECG) data at 400 Hz. Respiration was monitored with a pneumatic belt as part of the RAVANS procedure.

Respiration and ECG data were used to calculate respiratory rate, heart rate (HR), and heart rate variability (HRV). HRV analysis has been applied to indirectly estimate sympathetic and parasympathetic modulation to the heart [35–38]. While some controversy in interpretation remains, the spectral peak in a low-frequency band (LF, 0.01–0.15 Hz) is thought to be influenced by both parasympathetic and sympathetic activity, while the peak in a high-frequency band (HF, 0.15–0.50 Hz) is influenced solely by parasympathetic (cardiovagal) activity [37]. The LF/HF ratio has been used to approximate the balance between sympathetic and parasympathetic modulation to the heart. All physiological metrics were evaluated for 5-minute windows at baseline, and at the end of stimulus (window ending at termination of stimulus). ECG data were processed with the WFDB (Waveform Database) Software Package [39] and MATLAB 7.4.0 (The Mathworks, Inc., Natick, MA, USA). Data were automatically annotated with careful manual correction for QRS peak detection in order to form an R-R interval time series. Respiration rate and HRV were evaluated using spectral methods over the window of interest. We used a conventional fast Fourier transform (FFT)-based analysis using the Yule–Walker algorithm, a parametric spectral estimation method.

Within each window of interest, modulation of physiological metrics (HR, respiratory rate, LF-HRV, HF-HRV, and LF/HF) was evaluated with a 2 × 2 analysis of variance (ANOVA; PASW Statistics 18, SPSS Inc., Chicago, IL, USA) was performed with factors STIM (RAVANS and NVAS) and TIME (baseline and end-stim) as independent variables. Post hoc testing was performed with Student’s t-tests, significant at α = 0.05.

QST

Our primary outcome measures included psychophysical responses to several forms of noxious mechanical stimulation. QST measures serve as markers of sensitization and hyperalgesia, and have been studied as predictors of pain treatment outcomes. Prior research in a variety of patient samples has indicated that QST measures predict responses to opioid medications in both patients [40] and controls [41]. Other treatment studies have revealed that changes in responses to standardized noxious stimuli are associated with changes in clinical pain [42–45].

Because numerous studies have demonstrated that CPP is associated with generalized hyperalgesia at various body sites [26,46,47], we elected to study RAVANS’ impact on indices of hyperalgesia and central sensitization. Hence, we evaluated repeated mechanical stimuli that produce windup (a phenomenon related to central sensitization) and tonic, deep-tissue mechanical pain. During the session, subjects were seated comfortably in a reclining chair. Tonic, deep-tissue mechanical pain was assessed using an inflatable cuff. Cuff pressure algometry is a recently characterized method that is now included in many QST studies. In brief, tonic, deep-tissue mechanical stimulation is applied using a pneumatic tourniquet cuff, which is inflated to and maintained at a particular pressure [48]. One advantage to the application of cuff algometry is that unlike more superficial methods of evaluating mechanical sensitivity, cuff pain responses are unaffected by sensitization or desensitization of the skin, indicating that this procedure primarily assesses sensitivity in muscle and other deep tissues [49,50]. The present protocol utilized a Hokanson rapid cuff inflator, as in some of our previous cuff studies [51,52]. A standard blood pressure cuff was wrapped comfortably around the lower leg, over the gastrocnemius muscle. A computer-controlled air compressor maintained the pressure at a level that was individually tailored, for each subject, to produce a pain intensity rating of 40/100. Cuff inflation was maintained for 2 minutes, and subjects rated pain intensity and unpleasantness at 30-second intervals. Cuff pain intensity and unpleasantness were averaged across the 2-minute cuff stimulation period.

Mechanical probes were used to assess windup. First, as in previous work [53], participants underwent an assessment of mechanical temporal summation using a set of seven custom-made weighted pinprick stimulators developed by the German Research Network on Neuropathic Pain [54,55]. These punctuate mechanical probes have a flat contact area of 0.2 mm in diameter and exert forces between 8 and 512 mN. Punctate stimuli were delivered to the skin on the dorsum of the middle finger of the right hand. In each session, we determined the lowest force stimulator that produced a sensation of mild to moderate pain (128 or 256 mN for most subjects), and then applied a train of 10 stimuli at the rate of 1 per second. Participants rated the painfulness of the first, fifth, and tenth stimulus. All ratings were on a 0–100 verbal pain intensity scale used in previous studies [56,57]. We used these ratings to evaluate temporal summation of mechanical pain (i.e., the human analog to “windup”), a frequently used index of central pain facilitation. The assessment of temporal summation involves rapidly applying a series of identical noxious stimuli and determining the increase in pain across trials. Animal studies have suggested that temporal summation occurs centrally in second-order neurons in the spinal cord as a consequence of sustained C-fiber afferent input [58].

We also evaluated the two measures described earlier, concurrently, in order to study the modulatory effects of one stimulus on the other. Recent psychophysical pain research has recognized the role of endogenous inhibitory systems in shaping an individual’s perception of pain. In particular, diffuse noxious inhibitory control (DNIC) refers to one noxious stimulus inhibiting the pain produced by a second noxious stimulus [59]. DNIC depends on opioid-mediated supraspinal mechanisms [60], is a sensitive measure of deficits in pain modulation in fibromyalgia and...
related disorders [61], and predicts the development of long-term clinical pain [62]. In this study, we assessed the effects of RAVANS and NVAS stimulation on the magnitude of DNIC by assessing changes in the painfulness of punctuate mechanical stimulation during cuff algometry.

That is, at the conclusion of the 2-minute cuff stimulus, the sequence of 10 punctate mechanical probe stimuli was repeated while maintaining cuff inflation around the gastrocnemius.

Each set of pain responses (temporal summation, cuff algometry, and DNIC) was assessed at baseline, at the midpoint (15 minutes) of a half-hour-long period of RAVANS (or NVAS), immediately post-RAVANS (or post-NVAS), and 15 minutes after the conclusion of RAVANS (or NVAS). A 2 x 3 repeated measures ANOVA was performed on change scores from baseline. The factor with two levels was STIM (RAVANS vs NVAS), and the factor with three levels was TIME (change from baseline at the three time points: during stimulation, immediately after stimulation, and 15 minutes following the end of stimulation). Post hoc testing was performed with Student’s t-tests, significant at $\alpha = 0.05$.

Exploratory Outcomes

Exploratory, or secondary, outcome measures included clinical pain ratings (on a 0–10 scale), which were obtained at numerous time points during the psychophysical testing session. Sensations evoked by RAVANS and NVAS stimulation were assessed using a psychophysical instrument, the MGH Acupuncture Sensation Scale (MASS) scale, developed for acupuncture and acupuncture-like interventions [63]. The MASS scale can be summarized by the MASS index, which aggregates the breadth and depth of different sensations evoked by needle penetration and stimulation [63]. In addition, as in prior OST studies [64,65], current verbal ratings of anxiety (on a 0–100 scale, with “no anxiety” and “severe anxiety” as the respective anchors) were also obtained during the testing session.

Finally, we performed exploratory correlation analyses to evaluate if changes in perceived anxiety were correlated with changes in pain report for both cuff pain ratings and windup scores.

Results

A total of 18 women were enrolled in the study. Fifteen women completed the study. Their mean age was 36.3 years (standard deviation [SD] = 10.6, range = 20–58 years), and the mean pelvic pain duration was 12.3 years (SD = 9.2, range = 1–39 years). Subjects completed two experimental sessions, spaced at least 1 week apart (mean = approximately 2 weeks, range = 1–6 weeks). Three more subjects completed a single session but did not return for the second session. No subjects dropped out due to stimulus discomfort.

All of the subjects tolerated the RAVANS and NVAS procedures. The average electrical current intensity used for stimulation did not differ ($P = 0.31$) between RAVANS (0.43 ± 0.25 mA, $\mu \pm \sigma$) and NVAS (0.34 ± 0.20 mA). Similarly, the intensity of sensations evoked by the stimulation did not differ, as MASS index (assessed in only 9 of the 15 patients due to a paperwork error) did not differ ($P = 0.18$) across the testing sessions (RAVANS: 3.3 ± 2.3, $\mu \pm \sigma$; NVAS: 2.5 ± 1.4).

Subjects rated the pain intensity and unpleasantness evoked by cuff pressure. One subject’s cuff algometry data were dropped due to inadvertent within-session alterations in the cuff pressure. Hence, 14 participants are included in this analysis. Average cuff inflation pressure to reach a 40/100 pain rating did not differ ($P = 0.34$) between RAVANS (133.8 ± 43.0 mm Hg, $\mu \pm \sigma$) and NVAS (144.6 ± 45.4 mm Hg) visits. In addition, baseline cuff pain intensity and unpleasantness ratings did not differ across study visits ($P’s > 0.5$). A 2 x 3 repeated measures ANOVA with factors STIM and TIME demonstrated that for cuff pain intensity, a significant main effect of STIM was observed ($F_{1,13} = 4.7; P = 0.049; \eta^2 = 0.27$), with no significant main effect of TIME ($F_{2,12} = 1.8; P = 0.21$) or interaction ($F_{2,12} = 0.5; P = 0.65$). Follow-up t-tests (see Figure 3) revealed that cuff pain intensity ratings were reduced from baseline at each time point in both sessions ($P’s < 0.05$), but that the reduction tended to be larger in the RAVANS session for each time period: during the stimulation ($t_{[13]} = 1.9; P = 0.08$),
immediately after the stimulation ($t(13) = 2.0; \ P = 0.07$), and 15 minutes after the end of stimulation ($t(13) = 1.9; \ P = 0.08$). For cuff pain unpleasantness, neither main effect nor the interaction was significant ($P^*s > 0.1$).

Temporal summation of mechanical pain was calculated by subtracting the pain rating of the first stimulus from the maximum pain rating during the sequence of 10 punctate stimuli. The amount of temporal summation at baseline did not differ significantly ($P = 0.16$) between the RAVANS (30.7 ± 20.8, $\mu \pm \sigma$) and NVAS (20.7 ± 18.9) sessions. As with the cuff algometry data, a 2 (STIM) × 3 (TIME) repeated measures ANOVA was performed on temporal summation change scores from baseline. While no significant main effects of STIM ($F[1,14] = 1.1; \ P = 0.33$) or TIME ($F[2, 13] = 0.8; \ P = 0.45$) were observed, the interaction was significant ($F[2, 13] = 3.6; \ P = 0.04; \ \eta^2 = 0.20$). Follow-up $t$-tests (Figure 4) revealed that the only significant change from baseline was observed during stimulation in the RAVANS session ($P = 0.05$), and there was a similar trend for windup to be reduced immediately poststimulation in the RAVANS session ($P = 0.07$). At 15 minutes after RAVANS stimulation, and at all three time points in the NVAS session, there was no significant change from baseline in windup ($P^*s > 0.1$). Comparing change scores in the RAVANS and NVAS sessions, there was a trend for reductions in windup to be greater during stimulation in the RAVANS relative to the NVAS session ($t(15) = 1.8; \ P = 0.09$), but no trend for any session differences at the immediate poststimulation and 15-minute poststimulation time points ($P^*s > 0.4$).

DNIC was explored by evaluating temporal summation on the fingers during cuff algometry on the leg, at both RAVANS and NVAS sessions. At baseline, temporal summation of mechanical pain was unchanged during cuff algometry ($P^*s > 0.1$ for both RAVANS and NVAS), suggesting an absence of DNIC effects in these patients. A 2 × 3 repeated measures ANOVA on change scores from baseline revealed no significant main effects of TIME or STIM and no interaction ($P^*s > 0.1$).

Clinical pain was also explored by having patients rate (0–100) the intensity of their pelvic pain prior to QST and at each of the study time points. Pain ratings at baseline differed significantly ($P = 0.02$) between the RAVANS (32.8 ± 28.7, $\mu \pm \sigma$) and NVAS (mean = 44.0 ± 27.0) sessions. However, a 2 (STIM) × 3 (TIME) repeated measures ANOVA on change scores from baseline revealed no significant main effects of time or session and no interaction ($P^*s > 0.3$).

We also specifically assessed anxiety prior to QST at each of the study time points (Figure 5). Anxiety ratings at baseline did not differ significantly ($P = 0.12$) between the RAVANS (17.0 ± 16.9, $\mu \pm \sigma$) and NVAS (10.5 ± 17.2) sessions. A 2 × 3 ANOVA on change scores revealed a significant main effect of STIM ($F[1,14] = 9.1; \ P < 0.01; \ \eta^2 = 0.40$), but no main effect of TIME or interaction ($P^*s > 0.2$). Follow-up $t$-tests revealed that anxiety scores were lower (compared with baseline) at each of the subsequent time points in the RAVANS session ($P^*s < 0.01$), but there was no change from baseline at any time points in the NVAS session ($P^*s > 0.3$). Direct comparison of change scores at each time point indicated that reductions in anxiety were significantly larger in the RAVANS than the NVAS session at each time point ($P^*s < 0.05$).

We examined associations between changes in anxiety and changes in pain responses using correlation coefficients. Because correlations can be strongly affected by outlying values, we evaluated the distributions of change scores. Visual inspection of these distributions did not reveal any obvious outliers, and Grubb’s test indicated that no individual values were significant outliers ($P^*s > 0.05$). After Bonferroni correction for multiple comparisons, none of the correlations were significant ($P^*s > 0.05$), suggesting that treatment-associated changes in anxiety and treatment-associated changes in pain responses were largely independent.

While RAVANS stimulation specifically targeted afferent, and not efferent, vagal stimulation, physiological outflow variables (HR, respiratory rate, and HRV metrics) were evaluated to investigate potential feedback modulation of ANS outflow. These metrics were evaluated at baseline, before QST, and at the very end of RAVANS and NVAS stimulation. Due to excessive noise in the ECG signal (stemming from concurrent stimulation and line noise), the
endometriosis. RAVANS was also found to reduce anxiety levels. These reductions in pain responses and anxiety showed moderate to large effect sizes ($n^2 > 0.2$ [68]) and tended to be greater than those produced by control stimulation at auricular sites not innervated by the ABV nerve. Furthermore, analgesic responses were independent of reductions in anxiety, suggesting independent mechanisms. These results are promising and further longitudinal studies are warranted, utilizing QST and clinical outcomes as primary endpoints.

Analgesic effects of the auricular, noninvasive variant of VNS, t-VNS, have been evaluated by several studies in the previous decade. In healthy adults, Johnson et al. found that electrical stimulation of auricular locations, including the cavum concha (a noted site of ABV receptors), increased experimental pain threshold by 30–50% in a subset of subjects [67]. While we also did not find modulation of autonomic variables such as HR or HRV, we did find significant evoked pain analgesia in our group of CPP patients. Notable differences between our study and that of Johnson et al. included the group of subjects evaluated (i.e., CPP patients vs healthy adults), and the duration of stimulation, which was only 15 minutes in the study by Johnson et al. and was 30 minutes in our study. More interestingly, several previous longitudinal trials of electrical stimulation on three points on the auricle (one of which was the antihelix, noted to be innervated by vagal afferents [33]) have demonstrated analgesia for chronic low-back pain [68], cervical pain [69], and for acute pain during in vitro fertilization [70]. Similarly, future studies should also evaluate potential analgesia produced by RAVANS in a longitudinal trial in CPP and other chronic pain populations.

While RAVANS produced more significant analgesia compared with NVAS, some mild analgesia was also noted following this active control stimulation. Auricular vagal stimulation accesses higher brain regions through both the NTS and the SpV [17]. As our control stimulation provided input to great auricular nerve receptors localized on the ear lobe, the SpV nucleus would also be processing NVAS stimulation. Thus, the mild evoked pain analgesia imparted by NVAS stimulation, suggests that input to the SpV might also contribute to antinociception, although less significant compared with vagal input relayed by both NTS and SpV. In addition to the scientific rationale for being an active control, the lack of differences in stimulation parameters (e.g., current amplitude) or in subject ratings of the stimulation sensations between treatment conditions supports the credibility of NVAS as an active control.

Our lack of response in different cardiac autonomic variables (reflecting the safety of RAVANS) may simply reflect the innervation of the auricle, which is innervated by afferent, and not efferent, fibers of the vagus nerve [33], the latter of which innervates the chronotropic sinoatrial node of the heart. In fact, this specificity of innervation is one of the advantages of t-VNS stimulation over that of classical VNS stimulation, which affects both afferent and efferent branches of the main vagus nerve, with multiple sidebranches.
Analgesia Following Respiratory-Gated Auricular Vagal Stimulation

effects resulting from the stimulation of the latter. However, side effects for t-VNS via afferent–efferent vagal reflexes may also exist and include Arnold’s cough reflex (incidence 2.3–4.2%) [18,71], ear-gag reflex (~1.8%), ear-lacrimation reflex (~2%), and ear-syncpe reflex (~0.6%). Thus, feedback loops, similar to the more extensively studied autonomic baroreflex [72], also exist for ABV signaling, but are rare and we did not encounter any side effects consistent with such reflexes in our study. More interestingly, somatosensory afference tuned to the respiratory rhythm has been found in previous studies to modulate autonomic outflow. For instance, when stimulation was applied to the arm, gated to respiration, HR was found to decrease more substantially than for continuous stimulation at the same location [73]. Thus, future studies should continue to evaluate cardiac and other autonomic measures in response to RAVANS, as subtle modulations noted in this study may demonstrate significance with larger sample sizes and may ultimately relate to clinically relevant outcomes.

There is a dearth of studies exploring t-VNS mechanisms of action. The afferent vagus nerve, including the ABV, synapses bilaterally on the nucleus tractus solitarius (NTS) in the dorsal medulla of the brainstem. The NTS sends information to efferent (premotor) parasympathetic nuclei, including the dorsal motor nucleus of the vagus and the nucleus ambiguus, as well as higher brain regions known to modulate pain, such as the rostral ventromedial medulla, periaqueductal gray, and anterior cingulate cortex [74–77]. Thus, the NTS connects with a diffuse system of brain regions modulating pain. This supraspinal network of brain regions has been hypothesized to be the mechanistic substrate of VNS therapeutic effects [16]. In humans, Fallgatter et al. reported evoked brainstem potentials following t-VNS [78]. Additionally, functional magnetic resonance imaging has demonstrated that t-VNS modulates limbic brain regions and induces positive effects on mood [4]. The latter finding is supported by our data, which showed reduced anxiety following RAVANS, and not NVAS. Reduced anxiety was not correlated with reductions in pain outcomes, suggesting an independent mechanism specific to ABV stimulation. More study is needed on the neural mechanisms of t-VNS and on the optimum location for stimulation, as neither of these neuroimaging studies stimulated the cymba or cavum concha, instead focusing on the tragus, which was found by Peuker and Filler to be innervated by the ABV in only 45% of ears studied [33].

Future studies will need to more thoroughly optimize various stimulus parameters for longitudinal application of RAVANS. In clinical application, classical VNS uses stimulus parameters that vary depending on patient tolerance. However, typical usage includes a 30- to 90-second, 20–50-Hz (0.5 mS pulse width) burst of stimulation with current amplitude of 1–3 mA, which is applied every 5–10 minutes throughout the day [12]. Furthermore, the specific contribution of respiratory gating should be addressed by adding control intervention groups with ABV stimulation only during inspiration, intermittently irrespective of respiratory cycle, and/or continuously throughout the stimulus period. Important design parameters would have to be addressed, including whether stimulation in this control group is continuous at the same frequency (perhaps leading to greater energy input, but also more chance for habituation or sensitization, compared with respiratory-gated stimulation). Another option would be to have pulsed stimuli gated to exhalation (similar to RAVANS), but instead of a fixed delay, these control stimuli could occur after a random delay, i.e., during exhalation or inhalation for the next breath.

Several limitations should be noted. We did not find any reduction of clinical pain by either RAVANS or the control NVAS stimulation. This is not surprising given that chronic pain was assessed after a single treatment. Future studies may need to include longer-duration RAVANS stimulation over the course of multiple treatment sessions. Another issue is the effect size of the analgesia observed. Clinically significant analgesia for clinical pain outcomes is at least a 30% improvement [79]. For evoked pain outcomes (i.e., QST), no consensus has emerged to define the magnitude of clinically meaningful analgesia, and effects vary as a function of numerous factors such as the modality of the noxious stimulus, the location of its application, etc. [80]. However, recent studies of oral opioids have revealed that oxycodone reduces deep-tissue mechanical pain by approximately 15–25% in healthy volunteers [81,82] and by 40–50% in a study of chronic pain patients [29]. We report RAVANS-associated reductions of evoked pain ratings of approximately 30–50% in models of deep-tissue mechanical pain and mechanical temporal summation. This suggests that RAVANS stimulation may have effects on deep-tissue evoked pain that are comparable in magnitude with those of potent opioids such as oxycodone, although direct comparison studies would be necessary to confirm this. An additional limitation stems from the possibility that CPP patients may have disrupted central pain modulation circuitry [26–28]. While we did not find any significant DNIC effects during RAVANS stimulation, healthy subjects, who would have intact DNIC circuitry, should also be evaluated in future studies, as a comparison group. While we have included our rationale for not controlling for phase of menstrual cycle in our patient cohort, this lack of control should nevertheless be noted as another limitation. Finally, due to technical difficulties, we were not able to use the ECG signal in all subjects. Thus, the negative findings of RAVANS effects on autonomic outflow to the heart, while consistent with similar investigations in healthy adults [67], should be confirmed in future studies.

In conclusion, RAVANS demonstrated a trend for reduced evoked pain intensity and temporal summation of mechanical pain, and significantly reduced anxiety in CPP patients. Chronic pain disorders such as CPP are in great need of effective, nonpharmacological options for treatment. RAVANS produced promising antinociceptive effects for QST outcomes, reflective of the noted hyperalgesia and central sensitization in this patient population. Future studies should evaluate RAVANS for longitudinal reduction of both QST outcomes and clinical pain.
Acknowledgments

We would like to thank the National Institutes of Health for funding support (VN: R01-AT004714, P01-AT002048; RRE: R01-AQ034982, R21-A0057920; KP: F05-AT003770; ADW: K23-DA020681). Dr. Park was also supported by the Institute of Information Technology Advancement, Korea (IIITA-2008-[C1030-0801-0002]). The content is solely the responsibility of the authors and does not necessarily represent the official views of our sponsors.

References


11
Napadow et al.


Analgesia Following Respiratory-Gated Auricular Vagal Stimulation


